197 related articles for article (PubMed ID: 8137353)
1. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.
Kobayashi K; Jodrell DI; Ratain MJ
Cancer Surv; 1993; 17():51-78. PubMed ID: 8137353
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic studies in children with cancer.
Groninger E; Proost JH; de Graaf SS
Crit Rev Oncol Hematol; 2004 Dec; 52(3):173-97. PubMed ID: 15582785
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacodynamics of anticancer agents].
Ohtsu T; Sasaki Y
Gan To Kagaku Ryoho; 1993 Sep; 20(12):1741-9. PubMed ID: 8379667
[TBL] [Abstract][Full Text] [Related]
4. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.
Calvert H; Judson I; van der Vijgh WJ
Cancer Surv; 1993; 17():189-217. PubMed ID: 8137341
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
Shen M; Schilder RJ; Obasaju C; Gallo JM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of amonafide dosing based on acetylator phenotype.
Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Vogelzang NJ; Lane LB
Cancer Res; 1993 May; 53(10 Suppl):2304-8. PubMed ID: 8485716
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of cancer chemotherapy.
Alnaim L
J Oncol Pharm Pract; 2007 Dec; 13(4):207-21. PubMed ID: 18045780
[TBL] [Abstract][Full Text] [Related]
9. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring in cancer management.
Galpin AJ; Evans WE
Clin Chem; 1993 Nov; 39(11 Pt 2):2419-30. PubMed ID: 8222253
[TBL] [Abstract][Full Text] [Related]
11. [Clinical pharmacology in development of new anticancer agents].
Sasaki Y
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():310-4. PubMed ID: 7986109
[TBL] [Abstract][Full Text] [Related]
12. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic determinants of the activity and toxicity of antitumour agents.
Newell DR
Cancer Surv; 1989; 8(3):557-603. PubMed ID: 2701085
[TBL] [Abstract][Full Text] [Related]
14. The importance of pharmacokinetic limited sampling models for childhood cancer drug development.
Panetta JC; Iacono LC; Adamson PC; Stewart CF
Clin Cancer Res; 2003 Nov; 9(14):5068-77. PubMed ID: 14613983
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/pharmacodynamic modelling in oncological drug development.
Karlsson MO; Anehall T; Friberg LE; Henningsson A; Kloft C; Sandström M; Xie R
Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):206-11. PubMed ID: 15733216
[TBL] [Abstract][Full Text] [Related]
17. Adaptive control methods for the dose individualisation of anticancer agents.
Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
[TBL] [Abstract][Full Text] [Related]
18. Target concentration intervention in oncology: where are we at?
Saleem M; Dimeski G; Kirkpatrick CM; Taylor PJ; Martin JH
Ther Drug Monit; 2012 Jun; 34(3):257-65. PubMed ID: 22585183
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
Miller AA; Tolley EA; Niell HB
Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and cancer: successes, failures and future prospects.
Workman P
Cancer Surv; 1993; 17():1-26. PubMed ID: 8137337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
